Good morning, Amina

Semaglutide and cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease without diabetes35% read

Lindholm A, Okonkwo C, Varga M and 1 other · 1,204 citations

Key finding: Weekly semaglutide cut major cardiovascular events by 20% over 3.3 years versus placebo.

Why this paper: cites 2 papers you saved

Continuous glucose monitoring in non-diabetic heart failure: a pilot cohort

Nakamura H, Delacroix P · 41 citations

Key finding: A 40-patient pilot found no association with 90-day readmission.

Why this paper: new from an author you follow

External validation of a transformer triage model across four health systems

Iyer S, Novotny J, Haddad A and 2 others

Key finding: Performance fell from 0.91 to 0.78 AUROC at the two sites outside the training network.

Tirzepatide dosing in renal impairment

Whitfield R · 3 citations

Key finding: Dose reduction below eGFR 30 is not supported by the available data.

Sodium restriction and readmission after acute decompensation

Mensah K, Iyer S · 219 citations

No abstract was published with this record.

Wearable-derived atrial fibrillation burden and stroke risk

Bergström L, Chen W, Dlamini N · 88 citations

Key finding: Pooled across 11 cohorts, burden above 5.5 hours a day doubled ischaemic stroke risk.

Why this paper: trending in Cardiology